Pricing Log in Create free account

MannKind Corporation (MNKD) vs Urogen Pharma (URGN)

MannKind Corporation and Urogen Pharma are both Biotechnology companies. MannKind Corporation and Urogen Pharma are of similar size ($1.3B and $1.2B). Urogen Pharma grew revenue faster over the last twelve months: 159.3% against 31.7%. MannKind Corporation has the higher net margin (−18.1% vs −26.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, MannKind Corporation leads on 8 and Urogen Pharma on 8.

Valuation

Metric MNKD URGN Biotechnology median
P/E n/m n/m 10.60
P/S 3.04 5.01 9.40
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 50.23 n/m 0.66
EV/Sales 3.82 5.41 9.02
Earnings yield (5.87%) (5.32%) (32.88%)
Free cash flow yield (6.25%) (10.53%) (23.13%)

Profitability

Metric MNKD URGN Biotechnology median
Gross margin 0.00% 91.41% 68.51%
Operating margin (2.88%) (12.36%) 0.00%
Net margin (18.10%) (26.27%) 0.00%
Free cash flow margin (18.97%) (52.77%) 0.00%
Return on equity 182.90% 54.65% (51.96%)
Return on assets (12.29%) (28.78%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MNKD URGN Biotechnology median
Revenue growth (TTM) 31.74% 159.29% 6.76%
EPS growth (last fiscal year) (80.00%) (7.77%) 29.88%
Revenue growth, 5-year CAGR 39.89% 56.22% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MNKD URGN Biotechnology median
Debt to equity 0.00 (1.53) 0.00
Current ratio 2.22 3.40 4.97
Net debt to EBITDA 5.32 0.00 1.01

Dividend

Metric MNKD URGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric MNKD URGN Biotechnology median
Market cap 1.21b 1.26b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack